The study, published in the Annals of Internal Medicine, examined the safety and efficacy of Flu-v, a broad-spectrum flu vaccine that could become the highly anticipated universal flu vaccine, offering long-lasting protection and doing away with the need for annual flu shots.
Flu-v has been through phase 1 clinical trials that demonstrated it is safe. The current study is a phase 2 study and involved 175 healthy adults. The study participants were divided into two groups: one receiving Flu-v and the other receiving a placebo.
Researchers found that Flu-v elicited greater immune responses than a placebo, suggesting the vaccine increases the production of antibodies in the body.
The vaccine will now be tested for its effectiveness against flu infection in phase 3 clinical trials.
More articles on infection control:
Use of 2 central line catheters at once can up CLABSI risk, study shows
Here’s how a Hong Kong hospital tested 1,275 for coronavirus, and no employees got sick
14-day quarantine for coronavirus is appropriate, study suggests
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.